Quest Partners LLC Sells 4,190 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Quest Partners LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 86.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 659 shares of the biopharmaceutical company’s stock after selling 4,190 shares during the quarter. Quest Partners LLC’s holdings in Halozyme Therapeutics were worth $35,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rise Advisors LLC acquired a new stake in Halozyme Therapeutics during the first quarter worth approximately $25,000. Whittier Trust Co. bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $27,000. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the second quarter worth $33,000. Finally, Principal Securities Inc. acquired a new position in Halozyme Therapeutics in the fourth quarter valued at about $34,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 4.5 %

Shares of HALO opened at $59.50 on Friday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. Halozyme Therapeutics, Inc. has a 52 week low of $32.83 and a 52 week high of $65.53. The stock has a market capitalization of $7.57 billion, a price-to-earnings ratio of 24.59, a PEG ratio of 0.57 and a beta of 1.28. The stock has a fifty day moving average of $58.28 and a 200-day moving average of $49.02.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the company earned $0.68 earnings per share. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock worth $4,888,184 in the last quarter. 2.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group increased their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a research report on Thursday. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen raised their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Morgan Stanley boosted their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.